FDA
-
-
-
-
-
-
-
FDA grants orphan drug designation to Quoin's QRX003 for Netherton Syndrome
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
-
-
-
-
-
-
-
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
-
-
-
-
-
-
-
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
-
-
-
-
-
-
-
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
-
-
-
-
-
-
-
A Pivotal Year Ahead for Quoin Pharmaceuticals
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

